Drug Type Antibody–siRNA conjugates (ARC) |
Synonyms- |
Target |
Action antagonists, inhibitors, stimulants |
Mechanism EphA2 antagonists(Ephrin type-A receptor 2 antagonists), PLK1 inhibitors(Polo like kinase 1 inhibitors), RIG-I stimulants(Retinoic acid-inducible gene I stimulants) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | France | 01 Jul 2021 | |
| Neoplasms | Preclinical | France | 01 Jul 2021 |






